Rilvegostomig / Pembrolizumab / Carboplatin · Phase 3 Trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov · August 13, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a clinical trial registry entry for a Phase 3 study (ARTEMIDE-Lung02) that is currently recruiting participants. The trial will evaluate rilvegostomig combined with platinum-based chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment of locally advanced or metastatic squamous NSCLC. No efficacy or safety results are reported in this registry record.

What was studied

Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Non-small Cell Lung Cancer; age from 18 Years. Intervention: Arm A. Compared with: Arm B — Active Comparator. n = 1,160. 325 sites across 26 countries.

Key findings

Safety

This is a registry record with no efficacy or safety results posted

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a clinical trial registry record describing a Phase 3 study that is currently recruiting with no results posted; it documents planned design and endpoints only.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Overall survival (OS) (assessed at Up to approximately 6 years); Progression-free survival (PFS) (assessed at Up to approximately 6 years)

DesignPhase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose

PopulationNon-small Cell Lung Cancer; age from 18 Years

Sample size1,160

InterventionArm A

ComparatorArm B — Active Comparator

Setting325 sites across 26 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment1160

Study phasePhase 3

Primary outcome measure 1Overall survival (OS), up to approximately 6 years

Primary outcome measure 2Progression-free survival (PFS), up to approximately 6 years

Caveats

This is a registry record with no efficacy or safety results posted
Study is currently recruiting; no outcomes have been reported
Randomization method, blinding procedures, and allocation concealment are not described in this registry entry
Primary endpoint definitions and statistical analysis plan are not detailed in the available registry information

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Phase 3 interventional study with estimated enrollment of 1160 participants

Directness

strong

First-line treatment of locally advanced or metastatic squamous NSCLC

Consistency

insufficient

No results reported; cannot assess consistency

Risk of bias

insufficient

Registry record does not describe randomization, blinding, or allocation concealment methods

Sample adequacy

strong

Estimated enrollment of 1160 participants is adequate for Phase 3 design

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06692738). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1160 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer. Interventions: DRUG: Rilvegostomig; DRUG: Pembrolizumab; DRUG: Carboplatin; DRUG: Paclitaxel; DRUG: Nab-paclitaxel. Primary outcome measures: Overall survival (OS) , Up to approximately 6 years; Progression-free survival (PFS) , Up to approximately 6 years. Brief summary: The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT06692738RilvegostomigPembrolizumabCarboplatinAstraZenecaNon Small Cell Lung CancerPaclitaxel